Vitamin K2 / RadioS Cancer Research Results

VitK2, Vitamin K2: Click to Expand ⟱
Features:
Vitamin K2 (menaquinone)
Menaquinone-4 (MK-4), a subtype of vitamin K2 Helps blood clot, calcium metabolise and heart health.
Bone health: Vitamin K2 helps to regulate calcium levels in the body, which can help to prevent conditions such as osteoporosis and fractures.
Vitamin K2 has been studied for its potential role in cancer prevention and treatment. Some of the key findings include:
-Shown to inhibit the growth of cancer cells, including those found in leukemia, lung cancer, and prostate cancer.
-Shown to induce apoptosis (cell death) in cancer cells, which can help to prevent the spread of cancer.
-Shown to have anti-angiogenic effects, which means it can help to prevent the formation of new blood vessels that feed cancer cells.
-Synergistic effects with other nutrients, such as vitamin D and calcium, to enhance its anti-cancer effects.

UBIAD1 is the enzyme that makes MK-4 inside tissues

Vitamin K2 exists in several forms known as menaquinones, with MK-4 and MK-7 being the most studied. MK-4 is often used in Japan for therapeutic purposes, whereas MK-7 (derived from bacterial fermentation) is widely available as a supplement in Western countries.
For bone and cardiovascular health—and by extension, exploring potential anticancer benefits—doses for MK-7 commonly range from 90 to 200 micrograms per day.


RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)


Scientific Papers found: Click to Expand⟱
1824- VitK2,    Vitamin K and its analogs: Potential avenues for prostate cancer management
- Review, Pca, NA
AntiCan↑, toxicity∅, Risk↓, Apoptosis↑, ROS↑, TumCCA↑, eff↑, DNAdam↑, MMP↓, Cyt‑c↑, pro‑Casp3↑, FasL↑, Fas↑, TumAuto↑, ChemoSen↑, RadioS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

ROS↑, 1,  

Mitochondria & Bioenergetics

MMP↓, 1,  

Cell Death

Apoptosis↑, 1,   pro‑Casp3↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   FasL↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

DNA Damage & Repair

DNAdam↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 1,   eff↑, 1,   RadioS↑, 1,  

Functional Outcomes

AntiCan↑, 1,   Risk↓, 1,   toxicity∅, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RadioS, RadioSensitizer
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:168  Target#:1107  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page